- Home
- GLPG vs BBUC Comparison
GLPG vs BBUC Comparison
Compare GLPG & BBUC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLPG
- BBUC
- Stock Information
- Founded
- GLPG 1999
- BBUC 2022
- Country
- GLPG Belgium
- BBUC United States
- Employees
- GLPG N/A
- BBUC N/A
- Industry
- GLPG Biotechnology: Pharmaceutical Preparations
- BBUC
- Sector
- GLPG Health Care
- BBUC
- Exchange
- GLPG Nasdaq
- BBUC Nasdaq
- Market Cap
- GLPG 2.1B
- BBUC 2.4B
- IPO Year
- GLPG 2005
- BBUC N/A
- Fundamental
- Price
- GLPG $34.45
- BBUC $35.11
- Analyst Decision
- GLPG Sell
- BBUC
- Analyst Count
- GLPG 3
- BBUC 0
- Target Price
- GLPG $26.00
- BBUC N/A
- AVG Volume (30 Days)
- GLPG 203.5K
- BBUC 166.2K
- Earning Date
- GLPG 10-29-2025
- BBUC 11-06-2025
- Dividend Yield
- GLPG N/A
- BBUC 0.72%
- EPS Growth
- GLPG N/A
- BBUC N/A
- EPS
- GLPG N/A
- BBUC N/A
- Revenue
- GLPG $323,674,692.00
- BBUC $8,240,000,000.00
- Revenue This Year
- GLPG $1.77
- BBUC N/A
- Revenue Next Year
- GLPG $0.44
- BBUC N/A
- P/E Ratio
- GLPG N/A
- BBUC N/A
- Revenue Growth
- GLPG 5.43
- BBUC 6.96
- 52 Week Low
- GLPG $22.36
- BBUC $21.52
- 52 Week High
- GLPG $37.78
- BBUC $37.01
- Technical
- Relative Strength Index (RSI)
- GLPG 53.87
- BBUC 56.51
- Support Level
- GLPG $32.37
- BBUC $32.78
- Resistance Level
- GLPG $37.78
- BBUC $35.35
- Average True Range (ATR)
- GLPG 0.77
- BBUC 1.17
- MACD
- GLPG 0.00
- BBUC -0.03
- Stochastic Oscillator
- GLPG 39.37
- BBUC 69.23
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.
About BBUC Brookfield Business Corporation Exchangeable Subordinate Voting Shares
Brookfield Business Corp is a company established as a vehicle that owns and operates certain services and industrial operations on a world-wide basis and an alternative vehicle for investors who prefer investing in its operations through a corporate structure. Its goal is to generate returns through long-term capital appreciation with a modest distribution yield.